Biogen and Eisai trial drug in asymptomatic Alzheimer’s diseaseBiogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but Share XBiogen and Eisai trial drug in asymptomatic Alzheimer’s diseasehttps://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/
Biogen shares pop as it completes filing for Alzheimer’s drug aducanumabBiogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Share XBiogen shares pop as it completes filing for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/
FDA clears US trials of Green Valley’s Alzheimer’s drugChina’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing Share XFDA clears US trials of Green Valley’s Alzheimer’s drughttps://pharmaphorum.com/news/fda-clears-us-trials-of-green-valleys-of-alzheimers-drug/
Shionogi and Tetra expand partnership ahead of Alzheimer’s trial readoutShionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a Share XShionogi and Tetra expand partnership ahead of Alzheimer’s trial readouthttps://pharmaphorum.com/news/shionogi-and-tetra-expand-partnership-ahead-of-alzheimers-trial-readout/
Biogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapiesBiogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Share XBiogen and Sangamo work on Parkinson’s and Alzheimer’s gene therapieshttps://pharmaphorum.com/news/biogen-and-sangamo-work-on-parkinsons-and-alzheimers-gene-therapies/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
Is Tecfidera’s patent win a pyrrhic victory for Biogen?Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a Share XIs Tecfidera’s patent win a pyrrhic victory for Biogen?https://pharmaphorum.com/views-analysis-sales-marketing/tecfideras-patent-pyrrhic-victory-biogen/
Roche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseaseAs Biogen prepares for an FDA review of its amyloid-targeting Alzheimer’s drug aducanumab, Roche and Eli Lilly lifted Share XRoche and Lilly’s Alzheimer’s drugs draw blanks in inherited diseasehttps://pharmaphorum.com/news/roche-and-lillys-alzheimers-drugs-draw-blanks-in-inherited-disease/
Biogen gears up for Alzheimer’s drug launchThere are serious doubts about whether the FDA will approve Biogen’s Alzheimer’s candidate aducanumab – but is gearing Share XBiogen gears up for Alzheimer’s drug launchhttps://pharmaphorum.com/news/biogen-gears-alzheimers/
